ZYDUSLIFE:NSE:NSE-Zydus Lifesciences Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 887.45

Change

+15.80 (+1.81)%

Market Cap

USD 890.87B

Volume

0.66M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

-1.15 (-0.02%)

USD 1,513.85B
CIPLA:NSE Cipla Limited

+17.95 (+1.28%)

USD 1,191.84B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+48.45 (+1.65%)

USD 1,023.22B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+6.25 (+0.56%)

USD 970.36B
MANKIND:NSE Mankind Pharma Ltd

+4.05 (+0.18%)

USD 960.38B
LUPIN:NSE Lupin Limited

+56.90 (+2.91%)

USD 868.96B
AUROPHARMA:NSE Aurobindo Pharma Limited

+41.25 (+3.92%)

USD 639.93B
ABBOTINDIA:NSE Abbott India Limited

-91.80 (-0.29%)

USD 633.57B
ALKEM:NSE Alkem Laboratories Limited

+81.85 (+1.77%)

USD 593.38B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

+53.75 (+4.03%)

USD 373.94B

ETFs Containing ZYDUSLIFE:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.87% 80% B- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.87% 80% B- 81% B-
Trailing 12 Months  
Capital Gain -7.74% 42% F 53% F
Dividend Return 0.31% 23% F 25% F
Total Return -7.42% 42% F 52% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 42.86% 70% C- 59% D-
Dividend Return 43.37% 70% C- 58% F
Total Return 0.51% 49% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 37.23% 69% C- 66% D+
Risk Adjusted Return 116.50% 96% N/A 91% A-
Market Capitalization 890.87B 94% A 95% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.